Pharmaceutical R&D Pipeline News
Therapy Analysis - microRNA
Micro-Management
How microRNA could revolutionize traditional thinking on targeted drug development
The discovery of microRNA
Perhaps this is a time for turning old ideas on their heads. Novelty may create value, but has been slow to create blockbusters. An accidental discovery can bypass years of painstaking research. And DNA may make RNA (sometimes) – but RNA can do a great many other things besides making protein. The Human Genome Project yielded data on hundreds of hitherto unknown proteins, ripe for investigation as therapeutic targets – but this was not the end of the story. Hidden among the previously-unfashionable realm of ‘noncoding’ sequences lay what may emerge as the real master-regulators of biological systems, opening up a whole new area for pharmaceutical R&D, and one which seriously challenges our preconceptions regarding specificity of drug targeting.
Latest R&D News
Our news is available via RSS feed. If you are new to RSS news read about how to use it.
-
Aurograb dropped: Novartis to take financial hit
Mon, 01 Sep 2008 15:12:32 GMT
Novartis will be subject to a US$235 million impairment charge in the third quarter of 2008, following its decision to halt development of Aurograb... more -
NICE - Lucentis gets the seal of approval
Thu, 28 Aug 2008 10:51:30 GMT
The UK healthcare watchdog NICE has recommended Lucentis (ranibizumab), the age-related macular degeneration (AMD) therapeutic, for use in the National Health Service... more -
First ever approval for Freidreich's Ataxia therapeutic
Tue, 19 Aug 2008 11:09:46 GMT
Santhera Pharmaceuticals has received the first marketing authorisation in the world for a Freidreich's Ataxia therapy... more -
Intercell acquires Iomai
Mon, 11 Aug 2008 09:39:59 GMT
Austrian-based Intercell has acquired the American biotechnology firm Iomai for US$189 million... more
Mergers, Acquistions & Joint Ventures
- Stiefel Laboratories has acquired Barrier Therapeutics, which will remain as a subsidiary.
- Bentley spun-out all of its drug delivery products to Cpex.
- Intercell has acquired Iomai.
- Raven Biotechnologies has been acquired by MacroGenics.
New Drug Targets
Newly identified drug protein targets.
